Skip to content
DAT Supply Log in
Botanicals · Gummies

Lion's Mane Extract

Lion's Mane (Hericium erinaceus) is a medicinal mushroom traditionally used in East Asian herbalism. In gummy manufacturing, it is supplied as a polysaccharide-standardised extract. As a botanical on the EU on-hold list, it carries no authorised health claims under Reg. 432/2012, so brands typically position it around cognitive function and mental clarity without specific structure-function wording.

  • cognitive function
  • mental clarity
  • nervous system support
Build a formula with this ingredient
Lion's Mane Extract

At a glance

Definition
Lion's Mane (Hericium erinaceus) is a medicinal mushroom traditionally used in East Asian herbalism. In gummy manufacturing, it is supplied as a polysaccharide-standardised extract. As a botanical on the EU on-hold list, it carries no authorised health claims under Reg. 432/2012, so brands typically position it around cognitive function and mental clarity without specific structure-function wording.
Authorised wording (summary)
2 authorised statements — see "US structure-function statements" below.
Common positionings
  • cognitive function
  • mental clarity
  • focus and concentration
  • nervous system health
  • healthy ageing
Format suitability
Reviewed for gummies and sachets — confirmed per project.
Format & category fit

Where this ingredient fits in the DAT Supply catalogue

Every format chip links through to its manufacturing hub and to the private-label catalogue for that format. The category chip routes to the matching vertical hub on the categories index.

Positioning

What it is

Lion's Mane (Hericium erinaceus) is a medicinal mushroom native to North America, Europe, and Asia, recognised by its distinctive cascading spines. It has been used for centuries in traditional Chinese and Japanese medicine, and in recent decades has become one of the most commercially familiar functional mushrooms in the EU and US supplement markets. The active constituents are primarily polysaccharides (beta-glucans), hericenones, and erinacines, which are the focus of most standardised extracts used in gummy manufacturing.

Brands choose Lion's Mane for gummy ranges targeting cognitive function, mental clarity, and nervous system support. As a botanical on the EU on-hold list, it cannot carry EFSA-authorised health claims, but its strong consumer recognition and established safety profile make it a popular ingredient for daily wellness and healthy ageing positionings. It is typically co-formulated with B vitamins or other functional mushrooms to broaden the product's appeal.

Origin and history

Lion's Mane has been used in East Asian herbal medicine for centuries, particularly in China, Japan, and Korea, where it was traditionally prepared as a tea or decoction for general wellness. Its modern commercial journey began in Japan in the 1980s, where researchers isolated and characterised the hericenone and erinacine compounds that stimulate nerve growth factor (NGF) synthesis. This research catalysed global interest in the mushroom as a nootropic and neuroprotective botanical.

Industrial production today relies on controlled cultivation of the fruiting body on substrate, followed by hot water or ethanol extraction to concentrate the bioactive polysaccharides and terpenoids. The resulting extract is spray-dried to a fine powder that can be incorporated into gummy formulations. Standardisation to beta-glucan content (typically 30%) ensures batch-to-batch consistency, which is critical for commercial gummy manufacturing.

Scientific overview

The primary bioactive compounds in Lion's Mane are hericenones (found in the fruiting body) and erinacines (found in the mycelium), both of which have been shown in preclinical studies to stimulate nerve growth factor (NGF) synthesis. NGF is a protein essential for the growth, maintenance, and survival of neurons. Additionally, the polysaccharide fraction (beta-glucans) supports general immune modulation through interaction with gut-associated lymphoid tissue. These mechanisms underpin the ingredient's positioning for cognitive function and nervous system health.

Bioavailability of Lion's Mane compounds is moderate; oral administration results in measurable plasma levels of hericenones and erinacines, though first-pass metabolism reduces systemic exposure. Standardised extracts with higher beta-glucan content generally show more consistent bioavailability profiles. The choice between fruiting body extract and mycelial biomass affects both cost and potency — fruiting body extracts are more expensive but typically contain higher levels of hericenones.

From a manufacturing perspective, Lion's Mane extract is heat-stable and soluble in gummy matrices, making it suitable for standard gummy production processes. The mild umami flavour blends well with fruit flavours, though higher doses (above 1000 mg) may require flavour masking. Cost-per-mg is moderate compared to synthetic nootropics but higher than common vitamins and minerals. DAT confirms the optimal extract form and dosage per project based on target positioning and budget.

Why brands use Lion's Mane Extract

Lion's Mane is one of the most familiar and commercially understood functional mushroom actives across EU and US markets. Its positioning for cognitive function and mental clarity aligns with growing consumer demand for nootropic and brain-health supplements. Gummies offer a convenient, palatable format that overcomes the bitter taste of mushroom powders, making Lion's Mane accessible to a broader audience beyond traditional capsule users. Brands typically position it within daily wellness, healthy ageing, or functional mushroom ranges.

From a formulation standpoint, Lion's Mane extract is heat-stable and soluble in gummy matrices, which simplifies manufacturing. The mild umami character requires careful flavour balancing — fruit-forward profiles (berry, citrus, tropical) work well at standard doses. The main tradeoff is cost: standardised extracts are more expensive than whole mushroom powder, but they deliver consistent potency and better consumer perception. DAT reviews the extract specification and target dose per project to ensure the gummy is both manufacturable and commercially viable.

Pack copy for Lion's Mane gummies must respect the ingredient's on-hold regulatory status in the EU. Brands cannot make specific health claims about cognitive function, memory, or concentration under Reg. 432/2012. Instead, positioning should focus on general wellness, mental clarity, and nervous system support, with claim coverage coming from co-formulated nutrients such as Magnesium (for nervous system) or Vitamin B6 (for psychological function). DAT reviews all claim wording per project to ensure compliance with EU and UK regulations.

Supported formats

Formats this ingredient is reviewed for

DAT Supply covers gummy, capsule, softgel, tablet, powder, oral strip, liquid drop, shot, jelly and pet formats. The list below reflects every format this ingredient is reviewed for — chips link through to the manufacturing hub for each format. Final compatibility, dose and matrix are confirmed per project.

Formulation notes

Verified formulation reference across the formats this ingredient is reviewed for — the Supported formats section lists every product format this active is approved for, and the per-format Considerations section below covers matrix-specific guidance. Final formulation, dose and on-pack copy are confirmed per project.

Gummy fit
Good
Heat stable
Yes
Soluble in matrix
Yes
Cost tier
Medium

Forms available

  • polysaccharide-standardised extract (typically 30% beta-glucans)
  • whole fruiting body powder
  • mycelial biomass

Dosage reference

Brand positioning typically ranges from 500 mg to 3000 mg per serving. No reference-intake target reviewed per market established. DAT confirms target dose per project brief.

Taste & sensory

Mild umami character that blends well with fruit flavours in gummy formulations.

Manufacturing notes

Mushroom extracts require polysaccharide-standardised raw materials for batch consistency. Manufacturing and shelf-life stability are critical — DAT confirms per project with stability data.

Format considerations

Per-format formulation notes

Safe-baseline considerations for each format this ingredient is reviewed for. Final formulation, dose and on-pack copy are confirmed per project.

Gummies

  • Taste masking and aroma load against the cooked-base flavour — confirmed per project.
  • Heat exposure during cooking; coated or encapsulated forms may be required — confirmed per project.
  • Matrix choice (pectin vs gelatin) and its effect on ingredient stability — confirmed per project.
  • Per-gummy dose and serving count needed to hit the label claim — confirmed per project.

Develop in gummies →

Sachets

  • Powder flow and dose accuracy at single-serve sachet weights — confirmed per project.
  • Barrier requirements (oxygen, moisture) for the active — confirmed per project.
  • Reconstitution behaviour when the sachet is dosed into water — confirmed per project.

US structure-function statements

  • Supports cognitive function and mental clarity.Structure-function (DSHEA)
  • Helps maintain healthy nerve function.Structure-function (DSHEA)

Structure-function statements must appear with the FDA disclaimer in the same field of vision on the label. % Daily Value (DV) based on FDA 21 CFR 101.9.

Wording to avoid on pack copy

  • No disease claims (diagnose, treat, cure, or prevent any disease).
  • Structure-function claims must be accompanied by the FDA disclaimer: 'These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.'
  • No certification promises on pack until confirmed per project and batch documentation.
  • No guaranteed shelf-life on pack until confirmed with stability data.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Structure-function claims are permitted under DSHEA (21 USC §343(r)(6)). No Daily Value (DV) has been established for Lion's Mane under FDA 21 CFR 101.9.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Studies & evidence

External peer-reviewed sources and regulatory opinions. Citations only — DAT does not endorse the publishers.

  1. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T·Phytotherapy Research·2009

  2. Mori K, Ouchi K, Hirasawa N·Journal of Medicinal Food·2010

  3. Lai PL, Naidu M, Sabaratnam V, et al.·International Journal of Medicinal Mushrooms·2013

  4. Friedman M·Journal of Agricultural and Food Chemistry·2015

  5. EFSA Panel on Nutrition, Novel Foods and Food Allergens·EFSA Journal·2021

  6. Docherty S, Doughty FL, Smith EF·Nutrients·2023

Catalogue match

Product concepts featuring Lion's Mane Extract

Private-label product concepts where Lion's Mane Extract appears in the formula. Each opens to a product brief and quote route.

Synergies & conflicts

Pairs well with

Often co-formulated with other functional mushrooms (reishi, cordyceps, chaga) or with B vitamins for nervous system support.

Care when combining with

No known conflicts with common gummy actives. DAT reviews full formula compatibility per project.

Similar ingredients

Ingredients that frequently sit alongside this one in private-label supplement briefs.

Adjacent reading

Pairings, resource guides and blog notes most often associated with Lion's Mane Extract on DAT Supply briefs.

Common pairings

Ingredients that frequently co-formulate with Lion's Mane Extract.

Project handoff

Develop a formula featuring Lion's Mane Extract

A ready white-label formula exists — open a product brief, or talk to our team to align the launch plan.

Continue exploring

Quick context request

Get manufacturing context

Drop your work email and a member of the DAT team will follow up with the right context for this concept. Project documents, certificates and pricing are released through the project workspace in the DAT portal.

You will receive a short confirmation email. Project documents (specification, batch-specific COA, packaging documents) are released through the project workspace in the DAT portal once a brief is in place.